Patent Publication Number: US-2023143605-A1

Title: Kit and system for evaluating glioma and/or gastric adenocarcinoma prognosis

Description:
TECHNICAL FIELD 
     The disclosure relates to the field of biotechnology, in particular to a kit for evaluating glioma and/or gastric adenocarcinoma prognosis and a system for evaluating glioma and/or gastric adenocarcinoma prognosis. 
     BACKGROUND 
     Glioma is a general name of tumors derived from neuroepithelia, accounting for 40%-50% of craniocerebral tumors, and is the most common primary intracranial tumor. Gliomas are difficult to radically treat, the gliomas often relapse after the operation, and have a poor prognosis. The World Health Organization grading system divides the gliomas into grades I-IV according to the histological characteristics of the glioma, and the prognosis of different grades of gliomas varies. 
     Accurately evaluating the prognosis of glioma patients has important clinical, scientific and social values. In clinical work, accurate prognosis evaluation can guide doctors to formulate personalized examination and treatment schedules for high-risk patients and help the doctors to formulate reasonable reexamination and follow-up visit plans, thus improving the quality of medical services. In scientific research, accurately assessing the risk level of patients&#39; prognosis can provide an important basis for developing effective treatment schedules for high-risk patients, and can become an important reference for testing the effect of new treatments. From the perspective of society, accurate evaluation of the prognosis of patients can provide scientific survival expectations for patients and their families, guide the patients to comply with treatment plans, avoid excessive medical treatment, reduce family financial pressure, and help to improve the doctor-patient relationship. 
     At present, the evaluation of glioma prognosis is carried out mainly according to the pathological grade of glioma, but the prognosis of different patients with glioma of a same pathological grade may also vary greatly, and the evaluation of glioma prognosis is still not accurate enough only according to the pathological grade of glioma. 
     SUMMARY 
     The disclosure aims to provide a kit for evaluating glioma and/or gastric adenocarcinoma prognosis and a system for evaluating glioma and/or gastric adenocarcinoma prognosis, capable of further improveing the accuracy of evaluation of glioma and/or gastric adenocarcinoma prognosis. 
     In a first aspect, the disclosure provides a kit for evaluating glioma and/or gastric adenocarcinoma prognosis, where the kit includes a first primer pair capable of specifically amplifying a cDNA fragment of SEQ ID NO. 1, and/or a first probe capable of specifically hybridizing to the cDNA fragment of SEQ ID NO. 1, where the cDNA fragment of SEQ ID NO: 1 at least contains a cDNA sequence at positions 4057-4074, 4067-4084 or 4064-4079 of SEQ ID NO: 1. 
     Optionally, the cDNA fragment of SEQ ID NO: 1 at least contains a cDNA sequence at positions 4023-4122 of SEQ ID NO: 1; preferably, the cDNA fragment of SEQ ID NO: 1 refers to a cDNA sequence as shown in SEQ ID NO: 1. 
     Optionally, the first primer pair contains a first primer as shown in SEQ ID NO: 4 and a second primer as shown in SEQ ID NO: 5, and the sequence of the first probe contains a sequence as shown in SEQ ID NO: 6. 
     In a second aspect, the disclosure provides a kit for evaluating glioma and/or gastric adenocarcinoma prognosis, where the kit includes a second primer pair capable of specifically amplifying an mRNA fragment of SEQ ID NO. 2, and/or a second probe capable of specifically hybridizing to the mRNA fragment of SEQ ID NO. 2, where the mRNA fragment of SEQ ID NO: 2 at least contains an mRNA sequence at positions 2452-2469, 2464-2481 or 2458-2474 of SEQ ID NO: 2. 
     Optionally, the mRNA fragment of SEQ ID NO: 2 at least contains an mRNA sequence at positions 2416-2516 of SEQ ID NO: 2; preferably, the mRNA fragment of SEQ ID NO: 2 refers to an mRNA sequence as shown in the SEQ ID NO: 2. 
     Optionally, the second primer pair contains a third primer as shown in SEQ ID NO: 7 and a fourth primer as shown in SEQ ID NO: 8, and the sequence of the second probe contains a sequence as shown in SEQ ID NO: 9. 
     In a third aspect, the disclosure provides a kit for evaluating glioma and/or gastric adenocarcinoma prognosis, where the kit includes an antibody for resisting an amino acid fragment of SEQ ID NO. 3, where the amino acid fragment of SEQ ID NO. 3 at least contains an amino acid sequence at positions 750-764 of SEQ ID NO: 3. 
     Optionally, the amino acid fragment of SEQ ID NO. 3 at least contains an amino acid sequence at positions 722-764 of SEQ ID NO: 3; preferably, the amino acid fragment of SEQ ID NO. 3 refers to an amino acid sequence as shown in SEQ ID NO: 3. 
     In a fourth aspect, the disclosure provides application of a molecular reagent in preparation of a kit for evaluating glioma and/or gastric adenocarcinoma prognosis, where the molecular reagent includes at least one of (1)-(8) as follows: 
     (1) a cDNA as shown in SEQ ID NO. 1; 
     (2) a first primer pair capable of specifically amplifying the cDNA as shown in SEQ ID NO. 1; 
     (3) a first probe capable of specifically hybridizing to the cDNA as shown in SEQ ID NO. 1; 
     (4) an mRNA as shown in SEQ ID NO. 2; 
     (5) a second primer pair capable of specifically amplifying the mRNA as shown in SEQ ID NO. 2; 
     (6) a second probe capable of specifically hybridizing to the mRNA as shown in SEQ ID NO. 2; 
     (7) a protein as shown in SEQ ID NO. 3; and 
     (8) an antibody for resisting the protein as shown in SEQ ID NO. 3. 
     In a fifth aspect, the disclosure provides a system for evaluating glioma and/or gastric adenocarcinoma prognosis, where the system includes an amplification device, a sequencing device, a computing device and an output device. 
     The amplification device includes a collection unit and an amplification unit, where the collection unit is used for collecting a template nucleic acid fragment and an amplification primer, and the amplification unit is used for amplifying the template nucleic acid fragment by using the amplification primer to obtain an amplification product. 
     The sequencing device is used for sequencing the nucleic acid sequence of the amplification product to obtain a sequence of the amplification product. 
     The computing device includes a memory and a processor, where a computer program is stored in the memory, and the processor is configured to execute the computer program stored in the memory so as to achieve the following determination: 
     if the sequence of the amplification product contains the cDNA sequence as shown in SEQ ID NO. 1 and/or the mRNA sequence as shown in SEQ ID NO. 2, it is determined that the prognosis of glioma and/or gastric adenocarcinoma corresponding to the template nucleic acid fragment is poor. 
     The output device is used for outputting a determination result of the computing device. 
     Through the technical solution, the accuracy of evaluation of glioma and/or gastric adenocarcinoma prognosis is effectively improved in the disclosure. 
     Other features and advantages of the disclosure will be described in detail in the subsequent specific examples. 
    
    
     
       BRIEF DESCRIPTION OF THE DRAWINGS 
       The drawings are used to provide a further understanding of the disclosure and constitute a part of the description, and are used to explain the disclosure together with the following specific examples, but do not constitute limitations of the disclosure. In the drawings: 
         FIG.  1    is an agarose gel nucleic acid electrophoretogram of cDNA provided by the examples of the disclosure. 
         FIG.  2    is a diagram showing Sanger sequencing results of cDNA provided by the examples of the disclosure. 
         FIG.  3    is a survival curve graph of patients with a full-grade glioma sample provided by the examples of the disclosure. 
         FIG.  4    is a survival curve graph of patients with an IDH mutated full-grade glioma sample provided by the examples of the disclosure. 
         FIG.  5    is a survival curve graph of patients with a secondary glioblastoma sample provided by the examples of the disclosure. 
         FIG.  6    is a survival curve graph of patients with an IDH mutated secondary glioblastoma sample provided by the examples of the disclosure. 
         FIG.  7    is a survival curve graph of patients with a WHO grade III gastric adenocarcinoma sample provided by the examples of the disclosure. 
     
    
    
     DETAILED DESCRIPTION 
     The specific examples of the disclosure are described in detail below in combination with the drawings. It should be understood that the specific examples described herein are only used to illustrate and interpret the disclosure, but not to limit the disclosure. 
     In a first aspect, the disclosure provides a kit for evaluating glioma and/or gastric adenocarcinoma prognosis, where the kit includes a first primer pair capable of specifically amplifying a cDNA fragment of SEQ ID NO. 1, and/or a first probe capable of specifically hybridizing to the cDNA fragment of SEQ ID NO. 1, where the cDNA fragment of SEQ ID NO: 1 at least contains a cDNA sequence at positions  4057 - 4074 ,  4067 - 4084  or  4064 - 4079  of SEQ ID NO: 1. 
     Preferably, the cDNA fragment of SEQ ID NO: 1 at least contains a cDNA sequence at positions  4023 - 4122  of SEQ ID NO: 1; preferably, the cDNA fragment of SEQ ID NO: 1 refers to a cDNA sequence as shown in SEQ ID NO: 1. 
     The cDNA sequence as shown in SEQ ID NO: 1 is cDNA corresponding to a human MET gene with an exon 10 deleted. The inventors of the disclosure have found that when the cDNA can be reversely transcribed from mRNA of glioma and/or gastric adenocarcinoma cells, the malignant degree of glioma and/or gastric adenocarcinoma is higher, and the prognosis of patients is poorer. Where the cDNA fragment of SEQ ID NO: 1 contains a deletion site of the exon 10 of the human MET gene, the cDNA sequence shown in SEQ ID NO: 1 contains all exons, except the exon 10, of the human MET gene, and the sequence shown in SEQ ID NO: 1 is as follows: 
     
       
         
           
               
            
               
                 tacaagatgttgcatcactttactttaattgcatgatttatcagaacaac 
               
               
                   
               
               
                 tattaacatacgaagtaccattcagttcagctgcaggtataggcagtgac 
               
               
                   
               
               
                 aagtatctaattcttagaagaatcacttactcccacaatctgtccagaca 
               
               
                   
               
               
                 cattaatctaaggacaagtttataaatagcaaacgtgattttcacattgc 
               
               
                   
               
               
                 agtgttctcaagaatgtatatacaagtgtgtagtcctgttgatgggatgt 
               
               
                   
               
               
                 ttccccgagttctttctattgatgcgttcatgctcttgaccctggtagag 
               
               
                   
               
               
                 acagttctttctttccacagagcagattttcttttgtcatccaccattta 
               
               
                   
               
               
                 caatactctgtgaattagtattacttattacatttatgaaacggcaatat 
               
               
                   
               
               
                 ttggattgtaatagctcttcagtacaattccttgtgtcttctggtaagtc 
               
               
                   
               
               
                 tctgcactatcagagagcttttagttataatcattttcctgcaacaacag 
               
               
                   
               
               
                 ccaaactcaactattgagtttcagtgtgacacaccctctttgtagcttgc 
               
               
                   
               
               
                 tgggttaacccttggcttcaagtcctgatgatgtaatgagggtggggtgt 
               
               
                   
               
               
                 attggcaatcagtacatttccttatcgcaatttacagtcattgaaaatca 
               
               
                   
               
               
                 tgctgtcattaatcccagtctgacataccttttctaaaatgttcacagtg 
               
               
                   
               
               
                 cagtgtttttgtggcctaacaaaatttttctcatatcattaaaaataaac 
               
               
                   
               
               
                 atttttataaaaaatataacactttaaatgtttacgtcgacaaaaccagt 
               
               
                   
               
               
                 tagagtaacctacaccacatgcactatacagtagcaagcacaaaattcca 
               
               
                   
               
               
                 cagaatgaagcatcacaaagttctgctcagggtggctattccatctaggt 
               
               
                   
               
               
                 gaaatagctgggattttcaattgcctttttcatttgtttctaaagtatgt 
               
               
                   
               
               
                 tttgcttaacataaaacacaccctaatgcaaaataaaactccccaaaagt 
               
               
                   
               
               
                 tttgtttccaattgcttgcgaggtgggaacctgccaccgagacagaggct 
               
               
                   
               
               
                 aatcttttcaatccatccaccctttctttgctctacctatgagctgtgat 
               
               
                   
               
               
                 tggaaccaatgaaccttttagtaaaatgtatcctgctttacaaacatgct 
               
               
                   
               
               
                 gagttatctttaaaaatatttatcaacaaattacttgtcttattttgagt 
               
               
                   
               
               
                 tttcatttaaaaaaatacacacaaaacatctacatgttcacattcattag 
               
               
                   
               
               
                 atcagagtagcatcattctcaaacagtgggtttttatatgacaactaaat 
               
               
                   
               
               
                 atttcatgatgactaaattatttcatacaaattttcttaatgtcatctat 
               
               
                   
               
               
                 gtacattacatcctgttcatttataaacatgttttgtgtgatgctatttt 
               
               
                   
               
               
                 gaaactttgactgtattgcctataaatattcttccaaccaaaggaatgtc 
               
               
                   
               
               
                 tatacaaaaatttataagggctgggcgcagtggctcatgcctgtaatcct 
               
               
                   
               
               
                 agcactttgggaggctgaggtgggtggatttcttgagtccaggagtttga 
               
               
                   
               
               
                 aaccagccttggcaacatggcaaaaccccgtctctacaaaaaatacaaaa 
               
               
                   
               
               
                 attagccggggatggtggtgtgcgcctgtagtcccagctattcgggaggc 
               
               
                   
               
               
                 ttgagcctgggaggtggaggttgcagtgagctatgatcacaccactgcac 
               
               
                   
               
               
                 tacagccctggcaacagagtgagatcctgtctcaaaaaacaaacaaacat 
               
               
                   
               
               
                 ttaaaagggaatgtttacctaatgggtgaatgacaccatcagtaatgaaa 
               
               
                   
               
               
                 aatgttattgaccatacaacacacaaaagtgttttgaaacactagaattc 
               
               
                   
               
               
                 taaatgagtggcctgttctggggctgccgctcctgtcctgagcattacta 
               
               
                   
               
               
                 tctcttctgagttttctgtgatcaagaagccctcaatatttcctgcttca 
               
               
                   
               
               
                 atttcccatatgaaatcaagtggtacctgatttttaaaaaattcaaccca 
               
               
                   
               
               
                 gaattcaagttttggactccaatatgacaggagtgttgtcacggctgcag 
               
               
                   
               
               
                 gccattggtccgtggcctgtgggaccaagcctctggttctgatgctctgt 
               
               
                   
               
               
                 cagataagaaattccttagaatccagtaatttaaataacaatacaagtcc 
               
               
                   
               
               
                 tataatagtgcaattttggcaagagcaaagaatatcgatggccttttaaa 
               
               
                   
               
               
                 ggtcaggcagtgaaaaaaccattggacaaagtgtggactgttgctttgac 
               
               
                   
               
               
                 atagtactagcactatgatgtctcccagaaggaggctggtcgtgtgtcca 
               
               
                   
               
               
                 cctcatcatcagcgttatcttctgatgacaacagagaaggatacggagcg 
               
               
                   
               
               
                 acacattttacgttcacataagtagcgttcacatggacatagtgctcccc 
               
               
                   
               
               
                 aatgaaagtagagaagatcgctgatatccgggacaccagttcagaaaagg 
               
               
                   
               
               
                 atgggcgcatttcggctttagggtgccagcattttagcattacttcatat 
               
               
                   
               
               
                 aaggggtctgggcagtattcgggttgtaggagtcttctcccttgcaacaa 
               
               
                   
               
               
                 gtaaacagttatatcaaaggtgtttacgtcaggataaggtggggctcctc 
               
               
                   
               
               
                 ttgtcatcagctcccagaggagcacgccaaaggaccacacatctgacttg 
               
               
                   
               
               
                 gtggtaaacttttgagtttgcagactttccaaagccatccacttcactgg 
               
               
                   
               
               
                 cagctttgcacctgttttgttgtgtacactatagtattctttatcataca 
               
               
                   
               
               
                 tgtctctggcaagaccaaaatcagcaaccttgactgtgaatttttcatcc 
               
               
                   
               
               
                 agcatacagtttcttgcagccaagtctctgtggacaaactttttgcttgc 
               
               
                   
               
               
                 aagatatttcatgcctttggctacttgaagaccaaagccaataagatctt 
               
               
                   
               
               
                 ttacagttggattatgagtctcatttcgaatgaaatttcgaagatctcca 
               
               
                   
               
               
                 tgtttcatgtatggtaggaccaccagcggagacccttcacttcgcaggca 
               
               
                   
               
               
                 gattcccaggagcgagaggacattgggatgactaaaatctttcatgatga 
               
               
                   
               
               
                 ttccctcggtcagaaattgggaaacttctcctatgtcagtgattctgttc 
               
               
                   
               
               
                 aaggatttcacagcacagtgaattttcttgccatcattgtccaacaaagt 
               
               
                   
               
               
                 cccatgatatacacaaccaaaatgccctcttcctatgacttcattgaaat 
               
               
                   
               
               
                 gcacaatcaggctactgggcccaatcactacatgctgcactgcctggacc 
               
               
                   
               
               
                 agctctggatttagagcactgaggtcaatgtggacagtattttgcagtaa 
               
               
                   
               
               
                 tggactggatatatcagagtccccactagttaggatgggggacatgtctg 
               
               
                   
               
               
                 tcagaggatactgcacttgtcggcatgaaccgttctgagatgaattagga 
               
               
                   
               
               
                 aactgatcttctggaaaagtagctcggtagtctacagattcatttgaaac 
               
               
                   
               
               
                 catttctgtagttgggcttacacttcgggcacttacaagcctatccaaat 
               
               
                   
               
               
                 gaggagtgtgtactcttgcatcgtagcgaactaattcactgcccagatct 
               
               
                   
               
               
                 ttaatttgctttctctttttcagccacaggaaaaacccaagtagtaataa 
               
               
                   
               
               
                 cagtgctgttgatattgagacaacaccagcaatcaatcctgtgaaattct 
               
               
                   
               
               
                 gatctggttgaactattacttttccaaggacggttgaagaaattgcttgc 
               
               
                   
               
               
                 ttccactctatatttagctcgctgttcaatttcagcaggtcattggggac 
               
               
                   
               
               
                 cgtgcataaaacggcttcagaatgtaagtgtatattctcacagctcttat 
               
               
                   
               
               
                 ttccaacttttaacacttcacctttaactgcttcagggtcaatatcattt 
               
               
                   
               
               
                 cccttaatttccagtacattttcattgcccattgagatcatcactggctt 
               
               
                   
               
               
                 ttcaaaaggcttaaacacaggattatgtacataaatgagatcaaagtatt 
               
               
                   
               
               
                 tggaaaggatcccatctaacatgaaaaaggctttggttttcagggggagt 
               
               
                   
               
               
                 tgcagattcagctgttgcagggaaggagtggtacaacagattatctctga 
               
               
                   
               
               
                 attagagcgatgttgacatgcctaataaaagatttggttggatgaatttc 
               
               
                   
               
               
                 atagacaatgggatcttcacggtaactgaagatgcttgtctctcggttgg 
               
               
                   
               
               
                 ctaagtcaattttcaatttaacagcaaactcagttgaaatggtttgggct 
               
               
                   
               
               
                 ggggtataacattcaagaatactgtttgacacactttttaaagtacatgt 
               
               
                   
               
               
                 ttttccaccaattgaaatgtgtctagaattcccactgtttaggtaatttc 
               
               
                   
               
               
                 cagttaaagtaagtaaagtgccaccagccataggaccgtatttcggcgaa 
               
               
                   
               
               
                 atacttgttattacaggatccacataggagaatgtactgtattgtgttgt 
               
               
                   
               
               
                 cccgtggccatttgaaataattatggacatattgaaatgcttattcatgg 
               
               
                   
               
               
                 caggaccaactgtgcatttcaatgtattcatcgtgctctcacttaaagtc 
               
               
                   
               
               
                 aaggtgcagctctcatttccaaggagaactctagttttctttaaatcaaa 
               
               
                   
               
               
                 tttattattcctccgaaatccaaagtcccagccacatatggtcagccttg 
               
               
                   
               
               
                 tccctccttcaaggggtgcactatttgggaaaaccttgtagattgcaggc 
               
               
                   
               
               
                 agacagatctgttgagtccatgtcccgctcaggcattcctccgatcgcac 
               
               
                   
               
               
                 acatttgtcgtggcaccagccacactgaacaaagggtggggcagagaggc 
               
               
                   
               
               
                 attgactgcaggactggaaatgtctgcagcccaagccattcaatgggatc 
               
               
                   
               
               
                 ttcgtgatcttcttcccagtgataaccagtgtgtagccattttggtttaa 
               
               
                   
               
               
                 tgtatgctccacaatcacttctggagacactggatgggagtccaggagaa 
               
               
                   
               
               
                 aattcacatgaggggttgatggtcctgatcgagaaaccacaacctgcatg 
               
               
                   
               
               
                 aagcgaccctctgatgtcccaagattagctatggtgaggtctcctttaat 
               
               
                   
               
               
                 gaaggtggatatagatgttaagaggacttcgctgaattgacccatgaata 
               
               
                   
               
               
                 agtcaacgcgctgcaaagctgtggtaaactctgttcgatattcatcacgg 
               
               
                   
               
               
                 cgcgcttcacagcctgatgaatttctcagaagtgtcctattaaagcagtg 
               
               
                   
               
               
                 ctcatgattgggtccgtaaaaatgctggagacatctcacattgtttttgt 
               
               
                   
               
               
                 tgacgatcttgttgaagaagtcgttgacatatttgatagggaatgcacac 
               
               
                   
               
               
                 atggcagatcgatccattggttcggcagaatctggcttgctttgtgcgaa 
               
               
                   
               
               
                 caccccgaaaagaatgtcatcattcaggctggctcctatttgtctagcaa 
               
               
                   
               
               
                 gctgggccccaggcttgctgacatacgcagcctgaagtatattaaacact 
               
               
                   
               
               
                 tccttctttgtggatctcttttttctcttttctgtgagaatacactccag 
               
               
                   
               
               
                 aggcatttccatgtaggaatgcaatccagagtttatggaacagaacctga 
               
               
                   
               
               
                 ttattcttgtgtgaaaagtctgagcatctagagtttccctttggaccgtc 
               
               
                   
               
               
                 aagaagtaaataaaattgttgctttcaaaggcatggacatacttaatggg 
               
               
                   
               
               
                 gtaagaatctctgaactcaggtaaaacatcaatgtaggactggtccgtca 
               
               
                   
               
               
                 aaaacataaaaccatctttcgtttcctttagccttctcactgatatcgaa 
               
               
                   
               
               
                 tgcaatggatgatctgggaaataagaagaatttatggtattgcctacaaa 
               
               
                   
               
               
                 gaagttgatgaaccggtcctttacagatgaaaggactttggctcccaggg 
               
               
                   
               
               
                 cgctcaccacacagtcaggacactggctgggctcttctatctgtggggag 
               
               
                   
               
               
                 aatatgcagtgaacctccgactgtatgtcagcagtatgattgtggggaaa 
               
               
                   
               
               
                 gacatgtcgctggcaggtccctctgttgacgctgccacagctaatgagtt 
               
               
                   
               
               
                 gatcatcatagtaggtgtcgacaactagagccatgttgatgttatctttc 
               
               
                   
               
               
                 caaacacctcctgataaattggctttgctgctgcagtcctgacatgggaa 
               
               
                   
               
               
                 acaatctgggtgttccagcacaggcccagtcttgtactcagcaaccttct 
               
               
                   
               
               
                 gaaggtcttcctcatttaaaacataaatgtagttagtggcaccaaggaaa 
               
               
                   
               
               
                 atgtgatgctcatgtagaatgacattctggatgggtgtttccgcggtgaa 
               
               
                   
               
               
                 gttgggaagctgatacttcatattcacattcatctcggactttgctagtg 
               
               
                   
               
               
                 cctctttacactccccattgctcctctgcaccaaggtaaacaggagcacg 
               
               
                   
               
               
                 aggatgccaggtgcaagcacagcgggggccttcattatgagaggtttatc 
               
               
                   
               
               
                 tttcggtgcccaggaaccagtggagaagtcagcggcgcaaggaccacacg 
               
               
                   
               
               
                 cgcgctccgcgcctccccgcctcctctcagcaagtcagctgtcgccccgc 
               
               
                   
               
               
                 atctggctcgcgccctccactcggctccgcatctgctcacaaagcgctcg 
               
               
                   
               
               
                 gggcgccgcgggcggcgagggcctccgggtcacctgc. 
               
            
           
         
       
     
     Where the first primer pair only needs to able to specifically amplify the cDNA fragment of SEQ ID NO. 1, and preferably, the first primer pair can contain a first primer as shown in SEQ ID NO: 4 and a second primer as shown in SEQ ID NO: 5. The first probe only needs to be able to specifically hybridize to the cDNA fragment of SEQ ID NO. 1, and preferably, the sequence of the first probe can contain a sequence as shown in SEQ ID NO: 6. 
     Preferably, the sequence as shown in SEQ ID NO: 4 can be: 
     
       
         
           
               
               
            
               
                   
                 atccaaccaaatcttttattaggcatg. 
               
            
           
         
       
     
     The sequence as shown in SEQ ID NO: 5 can be: 
     
       
         
           
               
               
            
               
                   
                 cttctggaaaagtagctcggtagtct. 
               
            
           
         
       
     
     The sequence as shown in SEQ ID NO: 6 can be: 
     
       
         
           
               
               
            
               
                   
                 caaatcttttattaggcatgtcaacatc. 
               
            
           
         
       
     
     In a second aspect, the disclosure provides a kit for evaluating glioma and/or gastric adenocarcinoma prognosis, where the kit includes a second primer pair capable of specifically amplifying an mRNA fragment of SEQ ID NO. 2, and/or a second probe capable of specifically hybridizing to the mRNA fragment of SEQ ID NO. 2, where the mRNA fragment of SEQ ID NO: 2 at least contains an mRNA sequence at positions  2452 - 2469 ,  2464 - 2481  or  2458 - 2474  of SEQ ID NO: 2. 
     Preferably, the mRNA fragment of SEQ ID NO: 2 at least contains an mRNA sequence at positions  2416 - 2516  of SEQ ID NO:  2 ; preferably, the mRNA fragment of SEQ ID NO: 2 refers to an mRNA sequence as shown in the SEQ ID NO: 2. 
     Where the mRNA sequence as shown in SEQ ID NO: 2 is an RNA sequence complementary to the cDNA sequence as shown in SEQ ID NO: 1, and the sequence as shown in SEQ ID NO: 2 is as follows: 
     
       
         
           
               
            
               
                 gcaggugacccggaggcccucgccgcccgcggcgccccgagcgcuuugug 
               
               
                   
               
               
                 agcagaugcggagccgaguggagggcgcgagccagaugcggggcgacagc 
               
               
                   
               
               
                 ugacuugcugagaggaggcggggaggcgcggagcgcgcgugugguccuug 
               
               
                   
               
               
                 cgccgcugacuucuccacugguuccugggcaccgaaagauaaaccucuca 
               
               
                   
               
               
                 uaaugaaggcccccgcugugcuugcaccuggcauccucgugcuccuguuu 
               
               
                   
               
               
                 accuuggugcagaggagcaauggggaguguaaagaggcacuagcaaaguc 
               
               
                   
               
               
                 cgagaugaaugugaauaugaaguaucagcuucccaacuucaccgcggaaa 
               
               
                   
               
               
                 cacccauccagaaugucauucuacaugagcaucacauuuuccuuggugcc 
               
               
                   
               
               
                 acuaacuacauuuauguuuuaaaugaggaagaccuucagaagguugcuga 
               
               
                   
               
               
                 guacaagacugggccugugcuggaacacccagauuguuucccaugucagg 
               
               
                   
               
               
                 acugcagcagcaaagccaauuuaucaggagguguuuggaaagauaacauc 
               
               
                   
               
               
                 aacauggcucuaguugucgacaccuacuaugaugaucaacucauuagcug 
               
               
                   
               
               
                 uggcagcgucaacagagggaccugccagcgacaugucuuuccccacaauc 
               
               
                   
               
               
                 auacugcugacauacagucggagguucacugcauauucuccccacagaua 
               
               
                   
               
               
                 gaagagcccagccaguguccugacuguguggugagcgcccugggagccaa 
               
               
                   
               
               
                 aguccuuucaucuguaaaggaccgguucaucaacuucuuuguaggcaaua 
               
               
                   
               
               
                 ccauaaauucuucuuauuucccagaucauccauugcauucgauaucagug 
               
               
                   
               
               
                 agaaggcuaaaggaaacgaaagaugguuuuauguuuuugacggaccaguc 
               
               
                   
               
               
                 cuacauugauguuuuaccugaguucagagauucuuaccccauuaaguaug 
               
               
                   
               
               
                 uccaugccuuugaaagcaacaauuuuauuuacuucuugacgguccaaagg 
               
               
                   
               
               
                 gaaacucuagaugcucagacuuuucacacaagaauaaucagguucuguuc 
               
               
                   
               
               
                 cauaaacucuggauugcauuccuacauggaaaugccucuggaguguauuc 
               
               
                   
               
               
                 ucacagaaaagagaaaaaagagauccacaaagaaggaaguguuuaauaua 
               
               
                   
               
               
                 cuucaggcugcguaugucagcaagccuggggcccagcuugcuagacaaau 
               
               
                   
               
               
                 aggagccagccugaaugaugacauucuuuucgggguguucgcacaaagca 
               
               
                   
               
               
                 agccagauucugccgaaccaauggaucgaucugccaugugugcauucccu 
               
               
                   
               
               
                 aucaaauaugucaacgacuucuucaacaagaucgucaacaaaaacaaugu 
               
               
                   
               
               
                 gagaugucuccagcauuuuuacggacccaaucaugagcacugcuuuaaua 
               
               
                   
               
               
                 ggacacuucugagaaauucaucaggcugugaagcgcgccgugaugaauau 
               
               
                   
               
               
                 cgaacagaguuuaccacagcuuugcagcgcguugacuuauucauggguca 
               
               
                   
               
               
                 auucagcgaaguccucuuaacaucuauauccaccuucauuaaaggagacc 
               
               
                   
               
               
                 ucaccauagcuaaucuugggacaucagagggucgcuucaugcagguugug 
               
               
                   
               
               
                 guuucucgaucaggaccaucaaccccucaugugaauuuucuccuggacuc 
               
               
                   
               
               
                 ccauccagugucuccagaagugauuguggagcauacauuaaaccaaaaug 
               
               
                   
               
               
                 gcuacacacugguuaucacugggaagaagaucacgaagaucccauugaau 
               
               
                   
               
               
                 ggcuugggcugcagacauuuccaguccugcagucaaugccucucugcccc 
               
               
                   
               
               
                 acccuuuguucaguguggcuggugccacgacaaaugugugcgaucggagg 
               
               
                   
               
               
                 aaugccugagcgggacauggacucaacagaucugucugccugcaaucuac 
               
               
                   
               
               
                 aagguuuucccaaauagugcaccccuugaaggagggacaaggcugaccau 
               
               
                   
               
               
                 auguggcugggacuuuggauuucggaggaauaauaaauuugauuuaaaga 
               
               
                   
               
               
                 aaacuagaguucuccuuggaaaugagagcugcaccuugacuuuaagugag 
               
               
                   
               
               
                 agcacgaugaauacauugaaaugcacaguugguccugccaugaauaagca 
               
               
                   
               
               
                 uuucaauauguccauaauuauuucaaauggccacgggacaacacaauaca 
               
               
                   
               
               
                 guacauucuccuauguggauccuguaauaacaaguauuucgccgaaauac 
               
               
                   
               
               
                 gguccuauggcugguggcacuuuacuuacuuuaacuggaaauuaccuaaa 
               
               
                   
               
               
                 cagugggaauucuagacacauuucaauugguggaaaaacauguacuuuaa 
               
               
                   
               
               
                 aaagugugucaaacaguauucuugaauguuauaccccagcccaaaccauu 
               
               
                   
               
               
                 ucaacugaguuugcuguuaaauugaaaauugacuuagccaaccgagagac 
               
               
                   
               
               
                 aagcaucuucaguuaccgugaagaucccauugucuaugaaauucauccaa 
               
               
                   
               
               
                 ccaaaucuuuuauuaggcaugucaacaucgcucuaauucagagauaaucu 
               
               
                   
               
               
                 guuguaccacuccuucccugcaacagcugaaucugcaacucccccugaaa 
               
               
                   
               
               
                 accaaagccuuuuucauguuagaugggauccuuuccaaauacuuugaucu 
               
               
                   
               
               
                 cauuuauguacauaauccuguguuuaagccuuuugaaaagccagugauga 
               
               
                   
               
               
                 ucucaaugggcaaugaaaauguacuggaaauuaagggaaaugauauugac 
               
               
                   
               
               
                 ccugaagcaguuaaaggugaaguguuaaaaguuggaaauaagagcuguga 
               
               
                   
               
               
                 gaauauacacuuacauucugaagccguuuuaugcacgguccccaaugacc 
               
               
                   
               
               
                 ugcugaaauugaacagcgagcuaaauauagaguggaagcaagcaauuucu 
               
               
                   
               
               
                 ucaaccguccuuggaaaaguaauaguucaaccagaucagaauuucacagg 
               
               
                   
               
               
                 auugauugcugguguugucucaauaucaacagcacuguuauuacuacuug 
               
               
                   
               
               
                 gguuuuuccuguggcugaaaaagagaaagcaaauuaaagaucugggcagu 
               
               
                   
               
               
                 gaauuaguucgcuacgaugcaagaguacacacuccucauuuggauaggcu 
               
               
                   
               
               
                 uguaagugcccgaaguguaagcccaacuacagaaaugguuucaaaugaau 
               
               
                   
               
               
                 cuguagacuaccgagcuacuuuuccagaagaucaguuuccuaauucaucu 
               
               
                   
               
               
                 cagaacgguucaugccgacaagugcaguauccucugacagacaugucccc 
               
               
                   
               
               
                 cauccuaacuaguggggacucugauauauccaguccauuacugcaaaaua 
               
               
                   
               
               
                 cuguccacauugaccucagugcucuaaauccagagcugguccaggcagug 
               
               
                   
               
               
                 cagcauguagugauugggcccaguagccugauugugcauuucaaugaagu 
               
               
                   
               
               
                 cauaggaagagggcauuuugguuguguauaucaugggacuuuguuggaca 
               
               
                   
               
               
                 augauggcaagaaaauucacugugcugugaaauccuugaacagaaucacu 
               
               
                   
               
               
                 gacauaggagaaguuucccaauuucugaccgagggaaucaucaugaaaga 
               
               
                   
               
               
                 uuuuagucaucccaauguccucucgcuccugggaaucugccugcgaagug 
               
               
                   
               
               
                 aagggucuccgcuggugguccuaccauacaugaaacauggagaucuucga 
               
               
                   
               
               
                 aauuucauucgaaaugagacucauaauccaacuguaaaagaucuuauugg 
               
               
                   
               
               
                 cuuuggucuucaaguagccaaaggcaugaaauaucuugcaagcaaaaagu 
               
               
                   
               
               
                 uuguccacagagacuuggcugcaagaaacuguaugcuggaugaaaaauuc 
               
               
                   
               
               
                 acagucaagguugcugauuuuggucuugccagagacauguaugauaaaga 
               
               
                   
               
               
                 auacuauaguguacacaacaaaacaggugcaaagcugccagugaagugga 
               
               
                   
               
               
                 uggcuuuggaaagucugcaaacucaaaaguuuaccaccaagucagaugug 
               
               
                   
               
               
                 ugguccuuuggcgugcuccucugggagcugaugacaagaggagccccacc 
               
               
                   
               
               
                 uuauccugacguaaacaccuuugauauaacuguuuacuuguugcaaggga 
               
               
                   
               
               
                 gaagacuccuacaacccgaauacugcccagaccccuuauaugaaguaaug 
               
               
                   
               
               
                 cuaaaaugcuggcacccuaaagccgaaaugcgcccauccuuuucugaacu 
               
               
                   
               
               
                 ggugucccggauaucagcgaucuucucuacuuucauuggggagcacuaug 
               
               
                   
               
               
                 uccaugugaacgcuacuuaugugaacguaaaaugugucgcuccguauccu 
               
               
                   
               
               
                 ucucuguugucaucagaagauaacgcugaugaugagguggacacacgacc 
               
               
                   
               
               
                 agccuccuucugggagacaucauagugcuaguacuaugucaaagcaacag 
               
               
                   
               
               
                 uccacacuuuguccaaugguuuuuucacugccugaccuuuaaaaggccau 
               
               
                   
               
               
                 cgauauucuuugcucuugccaaaauugcacuauuauaggacuuguauugu 
               
               
                   
               
               
                 uauuuaaauuacuggauucuaaggaauuucuuaucugacagagcaucaga 
               
               
                   
               
               
                 accagaggcuuggucccacaggccacggaccaauggccugcagccgugac 
               
               
                   
               
               
                 aacacuccugucauauuggaguccaaaacuugaauucuggguugaauuuu 
               
               
                   
               
               
                 uuaaaaaucagguaccacuugauuucauaugggaaauugaagcaggaaau 
               
               
                   
               
               
                 auugagggcuucuugaucacagaaaacucagaagagauaguaaugcucag 
               
               
                   
               
               
                 gacaggagcggcagccccagaacaggccacucauuuagaauucuaguguu 
               
               
                   
               
               
                 ucaaaacacuuuuguguguuguauggucaauaacauuuuucauuacugau 
               
               
                   
               
               
                 ggugucauucacccauuagguaaacauucccuuuuaaauguuuguuuguu 
               
               
                   
               
               
                 uuuugagacaggaucucacucuguugccagggcuguagugcaguggugug 
               
               
                   
               
               
                 aucauagcucacugcaaccuccaccucccaggcucaagccucccgaauag 
               
               
                   
               
               
                 cugggacuacaggcgcacaccaccauccccggcuaauuuuuguauuuuuu 
               
               
                   
               
               
                 guagagacgggguuuugccauguugccaaggcugguuucaaacuccugga 
               
               
                   
               
               
                 cucaagaaauccacccaccucagccucccaaagugcuaggauuacaggca 
               
               
                   
               
               
                 ugagccacugcgcccagcccuuauaaauuuuuguauagacauuccuuugg 
               
               
                   
               
               
                 uuggaagaauauuuauaggcaauacagucaaaguuucaaaauagcaucac 
               
               
                   
               
               
                 acaaaacauguuuauaaaugaacaggauguaauguacauagaugacauua 
               
               
                   
               
               
                 agaaaauuuguaugaaauaauuuagucaucaugaaauauuuaguugucau 
               
               
                   
               
               
                 auaaaaacccacuguuugagaaugaugcuacucugaucuaaugaauguga 
               
               
                   
               
               
                 acauguagauguuuuguguguauuuuuuuaaaugaaaacucaaaauaaga 
               
               
                   
               
               
                 caaguaauuuguugauaaauauuuuuaaagauaacucagcauguuuguaa 
               
               
                   
               
               
                 agcaggauacauuuuacuaaaagguucauugguuccaaucacagcucaua 
               
               
                   
               
               
                 gguagagcaaagaaaggguggauggauugaaaagauuagccucugucucg 
               
               
                   
               
               
                 guggcagguucccaccucgcaagcaauuggaaacaaaacuuuuggggagu 
               
               
                   
               
               
                 uuuauuuugcauuaggguguguuuuauguuaagcaaaacauacuuuagaa 
               
               
                   
               
               
                 acaaaugaaaaaggcaauugaaaaucccagcuauuucaccuagauggaau 
               
               
                   
               
               
                 agccacccugagcagaacuuugugaugcuucauucuguggaauuuugugc 
               
               
                   
               
               
                 uugcuacuguauagugcaugugguguagguuacucuaacugguuuugucg 
               
               
                   
               
               
                 acguaaacauuuaaaguguuauauuuuuuauaaaaauguuuauuuuuaau 
               
               
                   
               
               
                 gauaugagaaaaauuuuguuaggccacaaaaacacugcacugugaacauu 
               
               
                   
               
               
                 uuagaaaagguaugucagacugggauuaaugacagcaugauuuucaauga 
               
               
                   
               
               
                 cuguaaauugcgauaaggaaauguacugauugccaauacaccccacccuc 
               
               
                   
               
               
                 auuacaucaucaggacuugaagccaaggguuaacccagcaagcuacaaag 
               
               
                   
               
               
                 agggugugucacacugaaacucaauaguugaguuuggcuguuguugcagg 
               
               
                   
               
               
                 aaaaugauuauaacuaaaagcucucugauagugcagagacuuaccagaag 
               
               
                   
               
               
                 acacaaggaauuguacugaagagcuauuacaauccaaauauugccguuuc 
               
               
                   
               
               
                 auaaauguaauaaguaauacuaauucacagaguauuguaaaugguggaug 
               
               
                   
               
               
                 acaaaagaaaaucugcucuguggaaagaaagaacugucucuaccaggguc 
               
               
                   
               
               
                 aagagcaugaacgcaucaauagaaagaacucggggaaacaucccaucaac 
               
               
                   
               
               
                 aggacuacacacuuguauauacauucuugagaacacugcaaugugaaaau 
               
               
                   
               
               
                 cacguuugcuauuuauaaacuuguccuuagauuaaugugucuggacagau 
               
               
                   
               
               
                 ugugggaguaagugauucuucuaagaauuagauacuugucacugccuaua 
               
               
                   
               
               
                 ccugcagcugaacugaaugguacuucguauguuaauaguuguucugauaa 
               
               
                   
               
               
                 aucaugcaauuaaaguaaagugaugcaacaucuugua. 
               
            
           
         
       
     
     Where the second primer pair only needs to be able to specifically amplify the mRNA fragment of SEQ ID NO. 2, and preferably, the second primer pair can contain a third primer as shown in SEQ ID NO: 7 and a fourth primer as shown in SEQ ID NO: 8. The second probe only needs to be able to specifically hybridize with the mRNA fragment of SEQ ID NO. 2, and preferably, the sequence of the second probe can contain a sequence as shown in SEQ ID NO: 9. 
     Preferably, the sequence as shown in SEQ ID NO: 7 can be: 
     
       
         
           
               
            
               
                 taatacgactcactatagggagcgatgttgacatgcctaataaaaga. 
               
            
           
         
       
     
     The sequence as shown in SEQ ID NO: 8 can be: 
     
       
         
           
               
               
               
            
               
                   
                   
                 gtgtgtcaaacagtattcttg. 
               
            
           
         
       
     
     The sequence as shown in SEQ ID NO: 9 can be: 
     
       
         
           
               
               
               
            
               
                   
                   
                 ttgacatgcctaataaaagatttggttg. 
               
            
           
         
       
     
     In a third aspect, the disclosure provides a kit for evaluating glioma and/or gastric adenocarcinoma prognosis, where the kit includes an antibody for resisting an amino acid fragment of SEQ ID NO. 3, where the amino acid fragment of SEQ ID NO. 3 at least contains an amino acid sequence at positions  750 - 764  of SEQ ID NO: 3. 
     Preferably, the amino acid fragment of SEQ ID NO. 3 at least contains an amino acid sequence at positions  722 - 764  of SEQ ID NO: 3; more preferably, the amino acid fragment of SEQ ID NO. 3 refers to an amino acid sequence as shown in SEQ ID NO: 3. 
     Where the amino acid sequence as shown in SEQ ID NO: 3 is an amino acid sequence encoded by the mRNA sequence as shown in SEQ ID NO: 2, and the amino acid sequence as shown in SEQ ID NO: 3 is as follows: 
     
       
         
           
               
            
               
                 MKAPAVLAPGILVLLFTLVQRSNGECKEALAKSEMNVNMKYQLPNFTAET 
               
               
                   
               
               
                 PIQNVILHEHHIFLGATNYIYVLNEEDLQKVAEYKTGPVLEHPDCFPCQD 
               
               
                   
               
               
                 CSSKANLSGGVWKDNINMALVVDTYYDDQLISCGSVNRGTCQRHVFPHNH 
               
               
                   
               
               
                 TADIQSEVHCIFSPQIEEPSQCPDCVVSALGAKVLSSVKDRFINFFVGNT 
               
               
                   
               
               
                 INSSYFPDHPLHSISVRRLKETKDGFMFLTDQSYIDVLPEFRDSYPIKYV 
               
               
                   
               
               
                 HAFESNNFIYFLTVQRETLDAQTFHTRIIRFCSINSGLHSYMEMPLECIL 
               
               
                   
               
               
                 TEKRKKRSTKKEVFNILQAAYVSKPGAQLARQIGASLNDDILFGVFAQSK 
               
               
                   
               
               
                 PDSAEPMDRSAMCAFPIKYVNDFFNKIVNKNNVRCLQHFYGPNHEHCFNR 
               
               
                   
               
               
                 TLLRNSSGCEARRDEYRTEFTTALQRVDLFMGQFSEVLLTSISTFIKGDL 
               
               
                   
               
               
                 TIANLGTSEGRFMQVVVSRSGPSTPHVNFLLDSHPVSPEVIVEHTLNQNG 
               
               
                   
               
               
                 YTLVITGKKITKIPLNGLGCRHFQSCSQCLSAPPFVQCGWCHDKCVRSEE 
               
               
                   
               
               
                 CLSGTWTQQICLPAIYKVFPNSAPLEGGTRLTICGWDFGFRRNNKFDLKK 
               
               
                   
               
               
                 TRVLLGNESCTLTLSESTMNTLKCTVGPAMNKHFNMSIIISNGHGTTQYS 
               
               
                   
               
               
                 TFSYVDPVITSISPKYGPMAGGTLLTLTGNYLNSGNSRHISIGGKTCTLK 
               
               
                   
               
               
                 SVSNSILECYTPAQTISTEFAVKLKIDLANRETSIFSYREDPIVYEIHPT 
               
               
                   
               
               
                 KSFIRHVNIALIQR. 
               
            
           
         
       
     
     Where the antibody for resisting the amino acid fragment of SEQ ID NO. 3 can be a monoclonal antibody and/or a polyclonal antibody. 
     In a fourth aspect, the disclosure provides application of a molecular reagent in preparation of a kit for evaluating glioma and/or gastric adenocarcinoma prognosis, where the molecular reagent includes at least one of (1)-(8) as follows: 
     (1) a cDNA as shown in SEQ ID NO. 1; 
     (2) a first primer pair capable of specifically amplifying the cDNA as shown in SEQ ID NO. 1; 
     (3) a first probe capable of specifically hybridizing to the cDNA as shown in SEQ ID NO. 1; 
     (4) an mRNA as shown in SEQ ID NO. 2; 
     (5) a second primer pair capable of specifically amplifying the mRNA as shown in SEQ ID NO. 2; 
     (6) a second probe capable of specifically hybridizing to the mRNA as shown in SEQ ID NO. 2; 
     (7) a protein as shown in SEQ ID NO. 3; and 
     (8) an antibody for resisting the protein as shown in SEQ ID NO. 3. 
     In a fifth aspect, the disclosure provides a system for evaluating glioma and/or gastric adenocarcinoma prognosis. The system includes an amplification device, a sequencing device, a computing device and an output device, where the amplification device includes a collection unit and an amplification unit, where the collection unit is used for collecting a template nucleic acid fragment and an amplification primer, and the amplification unit is used for amplifying the template nucleic acid fragment by using the amplification primer to obtain an amplification product; the sequencing device is used for sequencing the nucleic acid sequence of the amplification product to obtain a sequence of the amplification product; the computing device includes a memory and a processor, where a computer program is stored in the memory, and the processor is configured to execute the computer program stored in the memory so as to realize the following determination: if the sequence of the amplification product contains the cDNA sequence as shown in SEQ ID NO. 1 and/or the mRNA sequence as shown in SEQ ID NO. 2, it is determined that the prognosis of glioma and/or gastric adenocarcinoma corresponding to the template nucleic acid fragment is poor; and the output device is used for outputting a determination result of the computing device. 
     In a sixth aspect, the disclosure provides a method for evaluating glioma and/or gastric adenocarcinoma prognosis, where the method includes a step of detecting whether a to-be-detected glioma and/or gastric adenocarcinoma sample contains the cDNA fragment of SEQ ID NO. 1 and/or the mRNA fragment of SEQ ID NO. 2 and/or the amino acid fragment of SEQ ID NO. 3 as described above. If the to-be-detected glioma and/or gastric adenocarcinoma sample contains the cDNA fragment of SEQ ID NO. 1 and/or the mRNA fragment of SEQ ID NO. 2 and/or the amino acid fragment of SEQ ID NO. 3 as described above, it is indicated that the prognosis of glioma and/or gastric adenocarcinoma patients corresponding to the to-be-detected glioma and/or gastric adenocarcinoma sample is poorer. Where the cDNA and/or the mRNA can be detected by a method of PCR (Polymerase Chain Reaction), RT-RPA (Reverse Transcription-Recombinase Polymerase Amplification), nucleic acid hybridization or high-throughput sequencing, and the protein can be detected by immunoblotting. 
     The disclosure is further described in detail below by the examples. 
     PREPARATION EXAMPLE 
     This preparation example was used for obtaining glioma samples and obtaining total RNAs and total cDNAs therein. 
     1211 glioma samples were collected by using operations conforming to the standards of the medical ethical committee, and the pathological characteristics of each glioma sample were determined. Where for each patient from whom a sample was collected, the consent of himself or herself and his or her therapist was obtained before the sample was collected, having a written proof material. Where glioma was diagnosed by utilizing a pathological diagnosis method, the prognosis of the glioma samples was evaluated according to the overall survival of patients corresponding to the glioma samples, and the longer the overall survival of the patients is, the better the prognosis of the glioma is. The characteristics such as the gender, age, pathological grade, tumor category, and overall survival of the patients corresponding to the glioma samples are shown in Table 1. 
     
       
         
           
               
               
             
               
                 TABLE 1 
               
               
                   
               
               
                 Category 
                 Quantity 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
            
               
                 Total sample number 
                 1211 
               
               
                 World Health Organization pathological grade 
                   
               
               
                 Grade II 
                 328 
               
               
                 Grade III 
                 354 
               
               
                 Grade IV 
                 529 
               
               
                 Histopathological classification 
                   
               
               
                 Diffuse oligodendroglioma 
                 110 
               
               
                 Diffuse astrocytoma 
                 193 
               
               
                 Diffuse oligoastrocytoma 
                 25 
               
               
                 Anaplastic oligodendroglioma 
                 99 
               
               
                 Anaplastic oligoastrocytoma 
                 27 
               
               
                 Anaplastic astrocytoma 
                 228 
               
               
                 Glioblastoma 
                 529 
               
               
                 Tumor type 
                   
               
               
                 Primary 
                 710 
               
               
                 Recurrent 
                 347 
               
               
                 Secondary 
                 154 
               
               
                 Age 
                   
               
               
                 Median age 
                 42 
               
               
                 Distribution 
                 8-79 
               
               
                 Gender 
                   
               
               
                 Number of males (proportion) 
                 717 (59.2%) 
               
               
                 Overall survival 
                   
               
               
                 Median survival (95% confidence interval) 
                 863 (772-1023) 
               
               
                   
               
            
           
         
       
     
     The total RNAs of the glioma samples were extracted by using a DNA extraction kit (purchased from Qiagen) according to its operation instruction. The total RNAs were detected by an integrity analyzer, and it was confirmed that the RNA integrity number (RIN) of the total RNAs was larger than 7.0. Double-stranded cDNA was synthesized by using a reverse transcription kit (purchased from Invitrogen) according to its operation instruction and by taking the total RNAs as a template. 
     EXAMPLE 1 
     In this example, the cDNAs of the glioma samples synthesized by the preparation example were subjected to PCR verification. 
     Primers used for the PCR verification were the first primer as shown in SEQ ID NO: 4 and the second primer as shown in SEQ ID NO: 5. The PCR operation was carried out according to the instructions of synthetic primers and the PCR kit. The PCR product was subjected to agarose gel nucleic acid electrophoresis to show whether an amplification band existed or not, as shown in  FIG.  1   , the appearing amplification bands were recovered by using a DNA gel extraction kit (a QIAquick PCR purification kit, purchased from Qiagen), then Sanger sequencing was performed, and the sequencing result is shown in  FIG.  2   . 
     It can be known from  FIG.  1    and  FIG.  2    that the glioma samples have MET genes with an exon 10 deleted. 
     EXAMPLE 2 
     In this example, RNAs of the glioma samples collected in the preparation example were sequenced. 
     An RNA library was constructed from RNA of each sample by using a RNA library construction kit (purchased from Illumina), then RNA sequencing was performed on the RNA library by using a sequencing platform (Illumina HiSeq 2000), and glioma samples containing mRNA as shown in SEQ ID NO: 2 were screened from the RNA sequencing results as shown in Table 2. 
     
       
         
           
               
               
               
             
               
                 TABLE 2 
               
               
                   
               
               
                   
                 Glioma samples 
                 Glioma samples 
               
               
                   
                 with the  
                 with the sequence  
               
               
                   
                 sequence of SEQ 
                 of SEQ ID  
               
               
                 Category 
                 ID NO: 2 detected 
                 NO: 2 undetected 
               
               
                   
               
             
            
               
                   
               
            
           
           
               
               
               
            
               
                 Quantity 
                 14 
                 1197 
               
               
                 World Health Organization  
                   
                   
               
               
                 pathological grade 
                   
                   
               
               
                 Grade II 
                 2 
                 326 
               
               
                 Grade III 
                 1 
                 353 
               
               
                 Grade IV 
                 11 
                 518 
               
               
                 Histopathological classification 
                   
                   
               
               
                 Diffuse oligodendroglioma 
                 0 
                 110 
               
               
                 Diffuse astrocytoma 
                 2 
                 191 
               
               
                 Diffuse oligoastrocytoma 
                 0 
                 25 
               
               
                 Anaplastic oligodendroglioma 
                 0 
                 99 
               
               
                 Anaplastic oligoastrocytoma 
                 0 
                 27 
               
               
                 Anaplastic astrocytoma 
                 1 
                 227 
               
               
                 Glioblastoma 
                 11 
                 518 
               
               
                 Tumor type 
                   
                   
               
               
                 Primary 
                 6 
                 704 
               
               
                 Recurrent 
                 1 
                 346 
               
               
                 Secondary 
                 7 
                 147 
               
               
                 Age 
                   
                   
               
               
                 Median age 
                 47.5 
                 42 
               
               
                 Distribution 
                 29-60 
                 8-79 
               
               
                 Gender 
                   
                   
               
               
                 Number of males (proportion) 
                 9 (64.3%) 
                 708 (59.1%) 
               
               
                 Overall survival 
                   
                   
               
               
                 Median survival (95%  
                 200 (96-NA) 
                 872 (780-1047) 
               
               
                 confidence interval) 
                   
                   
               
               
                   
               
            
           
         
       
     
     It can be seen from Table 2 that 14 glioma samples containing mRNA shown in SEQ ID NO: 2 were detected with a median survival of 200 days, and 1197 glioma samples not containing the mRNA shown in SEQ ID NO: 2 were detected with a median survival of 872 days, which indicated that the prognosis of glioma containing the mRNA shown in SEQ ID NO: 2 was poor, so that the mRNA can be used for evaluating glioma prognosis. 
     Besides, in the full-grade glioma, the IDH-mutated full-grade glioma, the secondary glioblastoma and the IDH-mutated glioblastoma, the overall survival condition of the glioma samples containing the mRNA shown as the SEQ ID NO: 2 and the overall survival condition of the glioma samples not containing the mRNA shown as the SEQ ID NO: 2 were compared through a survival curve (a Kaplan-Meier curve). Results show that the glioma samples containing the mRNA as shown in SEQ ID NO: 2 were poor in overall survival, as shown in  FIGS.  3 - 6   . 
     Similarly, it can be proved that the overall survival of patients corresponding to a gastric adenocarcinoma sample containing the mRNA as shown in SEQ ID NO: 2 was poor, and the result is shown in  FIG.  7   . 
     The preferred examples of the disclosure are described in detail above in combination with the drawings, however, the disclosure is not limited to the specific details in the above examples, in the technical concept range of the disclosure, the technical solution of the disclosure can be subjected to various simple variations, and these simple variations all belong to the protection range of the disclosure. 
     In addition, it should be noted that the specific technical features described in the above examples can be combined in any suitable mode without contradiction. 
     In addition, various different examples of the disclosure can also be combined at will, and as long as the examples do not violate the idea of the disclosure, the examples also should be regarded as the contents disclosed by the disclosure.